IDWeek Highlights | Dr. Yi Shi  Comments on a Single-Center Cohort Study of Colistin Therapy for CRAB Pneumonia

IDWeek Highlights | Dr. Yi Shi  Comments on a Single-Center Cohort Study of Colistin Therapy for CRAB Pneumonia

Carbapenem-resistant Acinetobacter baumannii (CRAB) infection is considered one of the most challenging issues among carbapenem-resistant gram-negative bacteria (CRO) due to limited effective treatment options. Colistin, a polymyxin antibiotic used for "repurposing" in the treatment of CRAB, is one of the few choices available in China. A recent presentation at the 2023 IDWeek congress reported findings from a single-center cohort study conducted in South Korea, suggesting that colistin therapy for CRAB pneumonia lacks efficacy and is associated with an increased incidence of acute kidney injury (AKI) [1]. Dr. Yi Shi from Jinling Hospital, Nanjing University School of Medicine, provides an introduction and commentary on this study below.
Alexander Mundinger：

Alexander Mundinger：

Cost-Effectiveness of Breast Cancer Screening Editor's Note: The 2023 China Congress of Integrative Oncology (2023 CCHIO) will be held in Tianjin from November 16th to 19th, 2023. Dr. Alexander Mundinger,…

Prof. Zhong-Qiu Lin: Creating a Protective Umbrella for the Cancer Prevention and Treatment of Chinese Women

Protecting the health of Chinese women and providing a robust defense against gynecological cancer requires the integration of more resources and efforts in the field of gynecological cancer prevention and treatment. On the eve of the "2023 Chinese Congress on Holistic Integrative Oncology (2023 CCHIO)," Oncology Frontier interviewed Prof. Zhong-Qiu Lin, Chairman of the Cervical Cancer Professional Committee of the China Anti-Cancer Association and Sun Yat-sen Memorial Hospital, to discuss the current status of gynecological cancer prevention and treatment in China, recent advances in maintenance therapy for advanced-stage cases, and the developmental vision of the Cervical Cancer Professional Committee of the China Anti-Cancer Association.
ESMO Hot Topic | Professor Han Liang : Phase III MATTERHORN Study on the Verge of Success, Significant Improvement in pCR with Neoadjuvant Durvalumab for Gastric Cancer

ESMO Hot Topic | Professor Han Liang : Phase III MATTERHORN Study on the Verge of Success, Significant Improvement in pCR with Neoadjuvant Durvalumab for Gastric Cancer

The 2023 ESMO Annual Meeting took place from October 20th to 24th in Madrid, Spain. As a highly authoritative annual event in the field of oncology, it unveils cutting-edge advancements in cancer research each year. In the gastric cancer domain this year, the global Phase III MATTERHORN study on the anti-PD-L1 monoclonal antibody durvalumab was presented as a Late-breaking Abstract (LBA) with mid-term analysis results (Abstract No: LBA73). The interim analysis revealed a clinically and statistically significant increase in the pathologic complete response (pCR) rate with the neoadjuvant treatment regimen of durvalumab in combination with FLOT. The MATTERHORN study holds promise as the first positive neoadjuvant Phase III immunotherapy regimen for gastric cancer. "Oncology Frontier" is pleased to invite Professor Han Liang from Tianjin Medical University Cancer Institute to provide an in-depth interpretation of this study.